High-Risk Human Papillomavirus Prevalence and Genotypes Distribution: Baseline Findings from Cervical Cancer Screening with Alinity m among Women in Bulgaria
Background: Persistent high-risk human papillomavirus HPV (HR-HPV) infection is the most significant risk factor for epithelial cell changes, the development of high-grade squamous cell lesions, and the progression to cervical cancer. This study aimed to provide epidemiological data and assess the prevalence and genotype distribution of HR-HPV. Methods: Liquid-based cytology (LBC) samples from 190 Bulgarian women were simultaneously tested to identify HR-HPV genotypes and perform cytological analysis. HPV detection and genotyping were performed using the clinically validated Alinity m HR-HPV assay. This test provides detailed information on HPV16, HPV18, and HPV45 and categorizes the remaining 11 HR-HPV genotypes. Results: HR-HPV infection was detected in 16.8% of the women screened, with mean age of 38.2 (±9.8) years. Infection with HPV16 was seen in 5.3%, HPV18 positivity was 2.2% and genotype HPV45 was found in 1.0%. Abnormalities in LBC cytology were observed in 18.9% of women. HR-HPV positivity in normal cytology samples was 5.2% and 63.9% in abnormal smears. Conclusion: At present, there is a notable absence of official data concerning the substantial impact of HPV in Bulgaria. Presented baseline findings establish a foundational understanding of the prevalence and genotype distribution of HR-HPV within selected segments of the Bulgarian population.
References
[1]
Kombe Kombe, A.J., Li, B., Zahid, A., Mengist, H.M., Bounda, G., Zhou, Y., et al. (2021) Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. FrontiersinPublicHealth, 8, Article 552028. https://doi.org/10.3389/fpubh.2020.552028
[2]
Wang, W., Sawleshwarkar, S. and Piraveenan, M. (2025) Computational Approaches of Modelling Human Papillomavirus Transmission and Prevention Strategies: A Systematic Review. JournalofBiologicalDynamics, 19, Article ID: 2436376. https://doi.org/10.1080/17513758.2024.2436376
[3]
Zerbini, F.M., Crane, A., Kuhn, J.H., Simmonds, P. and Lefkowitz, E.J. (2025) Summary of Taxonomy Changes Ratified by the International Committee on Taxonomy of Viruses (ICTV)—General Taxonomy Proposals, 2025. JournalofGeneralVirology, 106, Article ID: 002116. https://doi.org/10.1099/jgv.0.002116
[4]
Hanft, W., Stankiewicz Karita, H., Khorsandi, N., Vohra, P. and Plotzker, R. (2025) Sexually Transmitted Human Papillomavirus and Related Sequelae. ClinicalMicrobiologyReviews, 38, e00085-23. https://doi.org/10.1128/cmr.00085-23
[5]
Ouh, Y.T., Kim, H.Y., Yi, K.W., Lee, N.W., Kim, H.J. and Min, K.J. (2024) Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Tri-age Strategy. Diagnostics, 14, Article 451. https://doi.org/10.3390/diagnostics14040451
[6]
Einstein, M.H., Schiller, J.T., Viscidi, R.P., Strickler, H.D., Coursaget, P., Tan, T., et al. (2009) Clinician’s Guide to Human Papillomavirus Immunology: Knowns and Unknowns. TheLancetInfectiousDiseases, 9, 347-356. https://doi.org/10.1016/s1473-3099(09)70108-2
[7]
Galati, L., Chiantore, M.V., Marinaro, M. and Di Bonito, P. (2024) Human Oncogenic Viruses: Characteristics and Prevention Strategies—Lessons Learned from Human Papillomaviruses. Viruses, 16, Article 416. https://doi.org/10.3390/v16030416
[8]
Lipsick, J. (2021) A History of Cancer Research: Tumor Viruses. ColdSpringHarborPerspectivesinBiology, 13, a035774. https://doi.org/10.1101/cshperspect.a035774
[9]
Kusakabe, M., Taguchi, A., Sone, K., Mori, M. and Osuga, Y. (2023) Carcinogenesis and Management of Human Papillomavirus-Associated Cervical Cancer. InternationalJournalofClinicalOncology, 28, 965-974. https://doi.org/10.1007/s10147-023-02337-7
[10]
Karao？lan, B.B. and ürün, Y. (2024) Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review. Viruses, 16, Article 667. https://doi.org/10.3390/v16050667
[11]
Gu, Y., Li, T., Zhang, M., Chen, J., Shen, F., Ding, J., et al. (2024) The Display between HPV Infection and Host Immunity in Cervical Cancer. FrontiersinBioscience-Landmark, 29, Article 426. https://doi.org/10.31083/j.fbl2912426
[12]
de Sanjosé, S., Serrano, B., Tous, S., Alejo, M., Lloveras, B., Quirós, B., et al. (2018) Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCICancerSpectrum, 2, pky045. https://doi.org/10.1093/jncics/pky045
[13]
Franco, E.L., Schlecht, N.F. and Saslow, D. (2003) The Epidemiology of Cervical Cancer. TheCancerJournal, 9, 348-359. https://doi.org/10.1097/00130404-200309000-00004
[14]
Ntuli, L., Mtshali, A., Mzobe, G., Liebenberg, L.J. and Ngcapu, S. (2022) Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection. FrontiersinCellularandInfectionMicrobiology, 12, Article 927131. https://doi.org/10.3389/fcimb.2022.927131
[15]
Cangelosi, G., Sacchini, F., Mancin, S., Petrelli, F., Amendola, A., Fappani, C., et al. (2025) Papillomavirus Vaccination Programs and Knowledge Gaps as Barriers to Implementation: A Systematic Review. Vaccines, 13, Article 460. https://doi.org/10.3390/vaccines13050460
[16]
Fashedemi, O., Ozoemena, O.C., Peteni, S., Haruna, A.B., Shai, L.J., Chen, A., et al. (2025) Advances in Human Papillomavirus Detection for Cervical Cancer Screening and Diagnosis: Challenges of Conventional Methods and Opportunities for Emergent Tools. AnalyticalMethods, 17, 1428-1450. https://doi.org/10.1039/d4ay01921k
[17]
Blanco, R. and Mu？oz, J.P. (2025) Molecular Insights into HR-HPV and HCMV Co-Presence in Cervical Cancer Development. Cancers, 17, Article 582. https://doi.org/10.3390/cancers17040582
[18]
World Health Organization (2024) WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention. World Health Organization. https://doi.org/10.2471/b09020
[19]
Goldstein, D.Y., Yang, T., Lucic, D., Zhang, Y., Cullum, R., Kostera, J., et al. (2025) Multi-center Evaluation of the Alinity M HR HPV Assay with Liquid-Based Cytology Cervical Specimens in the United States. MicrobiologySpectrum, 13, e01918-24. https://doi.org/10.1128/spectrum.01918-24
[20]
Banerjee, D., Mittal, S., Mandal, R. and Basu, P. (2022) Screening Technologies for Cervical Cancer: Overview. Cytojournal, 19, Article 23. https://doi.org/10.25259/cmas_03_04_2021
[21]
Martinelli, M., Giubbi, C., Di Meo, M.L., Perdoni, F., Musumeci, R., Leone, B.E., et al. (2023) Accuracy of Human Papillomavirus (HPV) Testing on Urine and Vaginal Self-Samples Compared to Clinician-Collected Cervical Sample in Women Referred to Colposcopy. Viruses, 15, Article 1889. https://doi.org/10.3390/v15091889
[22]
Huang, S., Gentil, L.G., Schmidt, C., Cullum, R., Zhang, Y., Nelson, K., et al. (2025) Comparative Clinical Performance of Alinity M HR HPV, Cobas 4800 HPV, and Cobas 6800 HPV for Cervical Cancer Screening. MicrobiologySpectrum, 13, e00589-25. https://doi.org/10.1128/spectrum.00589-25
[23]
Nayar, R. and Wilbur, D.C. (2017) The Bethesda System for Reporting Cervical Cytology: A Historical Perspective. ActaCytologica, 61, 359-372. https://doi.org/10.1159/000477556
[24]
Kovachev, S., Slavov, V. and Slavova, K. (2013) Prevalence of Human Papillomavirus Infection in Women in Some Cities and Regions of Bulgaria. JournalofMedicalVirology, 85, 1577-1584. https://doi.org/10.1002/jmv.23652
[25]
Kovachev, S. and Slavov, V. (2018) Prevalence of Human Papillomavirus Infection in Women in Bulgaria: A 2017 Update. JournalofMedicalVirology, 90, 1142-1149. https://doi.org/10.1002/jmv.25050
[26]
Yordanov, A., Vasileva-Slaveva, M., Galai, N., Faraggi, D., Kubelac, M.P., Tripac-Iacovleva, I., et al. (2023) Cancer of the Cervix in Bulgaria: Epidemiology of a Crisis. Healthcare, 11, Article 318. https://doi.org/10.3390/healthcare11030318
[27]
Bruni, L., Diaz, M., Castellsagué, X., Ferrer, E., Bosch, F.X. and de Sanjosé, S. (2010) Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. TheJournalofInfectiousDiseases, 202, 1789-1799. https://doi.org/10.1086/657321
[28]
Berza, N., Zodzika, J., Kivite-Urtane, A., Baltzer, N., Curkste, A., Pole, I., et al. (2024) Understanding the High-Risk Human Papillomavirus Prevalence and Associated Factors in the European Country with a High Incidence of Cervical Cancer. EuropeanJournalofPublicHealth, 34, 826-832. https://doi.org/10.1093/eurpub/ckae075
[29]
Eroglu, S. and Asgin, N. (2020) Frequency and Genotype Distribution of High-Risk Human Papilloma Virus Types in Karabuk Province, Turkey: A Hospital Based Cross-Sectional Study. AnnalsofMedicalResearch, 27, 765-769. https://doi.org/10.5455/annalsmedres.2019.12.787
[30]
Hancer, V., Buyukdogan, M., Bylykbashi, I., Oksuz, B. and Acar, M. (2018) Prevalence of Human Papilloma Virus Types in Turkish and Albanian Women. JournalofCytology, 35, 252-254. https://doi.org/10.4103/joc.joc_162_17
[31]
Taskin, M., Nursal, A., Oruc, M. and Kariptas, E. (2022) Genotype Distribution and Prevalence of High-Risk Human Papillomavirus Infection among Women in Samsun Province of Turkey. AsianPacificJournalofCancerPrevention, 23, 2477-2482. https://doi.org/10.31557/apjcp.2022.23.7.2477
[32]
Piana, A., Sotgiu, G., Castiglia, P., Pischedda, S., Cocuzza, C., Capobianco, G., et al. (2011) Prevalence and Type Distribution of Human Papillomavirus Infection in Women from North Sardinia, Italy. BMCPublicHealth, 11, Article No. 785. https://doi.org/10.1186/1471-2458-11-785
[33]
Bergman, H., Henschke, N., Villanueva, G., Loke, Y.K., Golder, S.P., Dwan, K., et al. (2022) Human Papillomavirus (HPV) Vaccination for the Prevention of Cervical Cancer and Other HPV-Related Diseases: A Network Meta-Analysis. CochraneDatabaseofSystematicReviews, 11, CD015364. https://doi.org/10.1002/14651858.cd015364
[34]
Glinska, P., Macios, A., Jaworski, R., Bobinski, M., Pruski, D., Przybylski, M., et al. (2024) Baseline Data on Distribution of Human Papillomavirus (HPV) Genotypes in Cervical Samples of Gynecological Patients before Implementation of Population-Based HPV Vaccination Program in Poland. GinekologiaPolska, 95, 870-878. https://doi.org/10.5603/gpl.101436
[35]
Elfstrom, K.M., Smelov, V., Johansson, A.L.V., Eklund, C., Naucler, P., Arnheim-Dahlstrom, L., et al. (2014) Long Term Duration of Protective Effect for HPV Negative Women: Follow-Up of Primary HPV Screening Randomised Controlled Trial. BMJ, 348, g130-g130. https://doi.org/10.1136/bmj.g130
[36]
Holl, K., Nowakowski, A.M., Powell, N., McCluggage, W.G., Pirog, E.C., Collas De Souza, S., et al. (2015) Human Papillomavirus Prevalence and Type‐distribution in Cervical Glandular Neoplasias: Results from a European Multinational Epidemiological Study. InternationalJournalofCancer, 137, 2858-2868. https://doi.org/10.1002/ijc.29651
[37]
U？akar, V., Poljak, M., O？trbenk, A. and Klavs, I. (2014) Pre-Vaccination Prevalence of Infections with 25 Non-High-Risk Human Papillomavirus Types among 1,000 Slovenian Women in Cervical Cancer Screening. JournalofMedicalVirology, 86, 1772-1779. https://doi.org/10.1002/jmv.23997
[38]
Merdzhanova-Gargova, Y., Ivanova, M., Mollova-Kysebekirova, A., Mihaylova, A., Parahuleva-Rogacheva, N., Uchikova, E., et al. (2025) Advancements in Cervical Cancer Screening: Enhancing HPV Testing and Triage Strategies for Improved Risk Assessment. Biomedicines, 13, Article 1768. https://doi.org/10.3390/biomedicines13071768
[39]
OECD (2024) Beating Cancer Inequalities: Current Trends and Key Policy Directions. Organisation for Economic Cooperation Development.
[40]
Lebanova, H., Stoev, S., Naseva, E., Getova, V., Wang, W., Sabale, U., et al. (2023) Economic Burden of Cervical Cancer in Bulgaria. InternationalJournalofEnvironmentalResearchandPublicHealth, 20, Article 2746. https://doi.org/10.3390/ijerph20032746
[41]
Shikova, E., Todorova, I., Ganchev, G., Kouseva-Dragneva, V. and Kalascheva-Zaimova, P. (2011) Prevalence of Human Papillomavirus Infection among Female Sex Workers in Bulgaria. InternationalJournalofSTD&AIDS, 22, 278-280. https://doi.org/10.1258/ijsa.2009.009362
[42]
Grozdanov, P., Zlatkov, V., Ganchev, G., Karagiosov, I., Toncheva, D. and Galabov, A.S. (2014) HPV Prevalence and Type Distribution in Women with Normal or Abnormal Pap Smear in Bulgaria. JournalofMedicalVirology, 86, 1905-1910. https://doi.org/10.1002/jmv.24020
[43]
Rahangdale, L., Mungo, C., O’Connor, S., Chibwesha, C.J. and Brewer, N.T. (2022) Human Papillomavirus Vaccination and Cervical Cancer Risk. BMJ, 379, e070115. https://doi.org/10.1136/bmj-2022-070115
[44]
Spinillo, A., Dal Bello, B., Gardella, B., Roccio, M., Dacco’, M.D. and Silini, E.M. (2009) Multiple Human Papillomavirus Infection and High Grade Cervical Intraepithelial Neoplasia among Women with Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low Grade Squamous Intraepithelial Lesions. GynecologicOncology, 113, 115-119. https://doi.org/10.1016/j.ygyno.2008.12.037
[45]
Zhang, Y., Zhao, F.H., Hu, S.Y., Zhao, X.L. and Qiao, Y.L. (2021) Interpretation of “WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, Second Edition. Chinese Journal of Medical History, 101, 2653-2657. (In Chinese)
[46]
Luu, X.Q., Jun, J.K., Suh, M., Oh, J., Yu, S. and Choi, K.S. (2025) Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination. JAMANetworkOpen, 8, e2526683. https://doi.org/10.1001/jamanetworkopen.2025.26683
[47]
Zhou, L., Li, Y., Wang, H., Qin, R., Han, Z. and Li, R. (2025) Global Cervical Cancer Elimination: Quantifying the Status, Progress, and Gaps. BMCMedicine, 23, Article No. 67. https://doi.org/10.1186/s12916-025-03897-3
[48]
Todorova, I., Panayotova, Y., Kotzeva, T., Greenley, R. and McKee, M. (2026) Cervical Cancer in Bulgaria since EU Accession in 2007: A Struggle in the Face of Political Instability. HealthPolicy, 164, Article ID: 105497. https://doi.org/10.1016/j.healthpol.2025.105497
[49]
Clarke, M.A., Risley, C., Stewart, M.W., Geisinger, K.R., Hiser, L.M., Morgan, J.C., et al. (2021) Age-Specific Prevalence of Human Papillomavirus and Abnormal Cytology at Baseline in a Diverse Statewide Prospective Cohort of Individuals Undergoing Cervical Cancer Screening in Mississippi. CancerMedicine, 10, 8641-8650. https://doi.org/10.1002/cam4.4340
